For the twelve months ended Jun 30, 2026, Picard Medical Inc. reported $6.30M of revenue and -$27.99M of net income.
PMI revenue was $2.95M in fiscal Q2 2026 (ended Jun 30, 2026), up 38.6% from a year earlier and up 156.9% from the prior quarter. For the full fiscal 2025 it was $4.94M, up 12.5% from fiscal 2024.
PMI net income was -$5.66M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$6.72M a year earlier. For the full fiscal 2025 it was -$27.00M, compared with -$21.05M in fiscal 2024.
PMI free cash flow was -$1.35M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$2.54M a year earlier.
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Revenue | $4.94M | $4.39M |
| Cost of revenue | $5.14M | $4.50M |
| Gross profit | -$204.0K | -$112.0K |
| Research and development | $3.05M | $3.38M |
| Selling, general and admin | $10.00M | $10.22M |
| Operating income | -$13.26M | -$13.71M |
| Pre-tax income | -$26.97M | -$21.07M |
| Income tax | $35.0K | -$15.0K |
| Net income | -$27.00M | -$21.05M |
| EPS, basic | -$0.75 | -$2.99 |
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Cash and equivalents | $7.45M | $96.0K |
| Receivables | - | $513.0K |
| Inventory | $7.30M | $8.12M |
| Current assets | $20.73M | $9.79M |
| Goodwill | $615.0K | $615.0K |
| Total assets | $22.55M | $12.11M |
| Current liabilities | $18.70M | $35.33M |
| Total liabilities | $18.76M | $35.84M |
| Shareholders' equity | $3.79M | -$44.00M |
| Line item | Dec 31, 2025 | Dec 31, 2024 |
|---|---|---|
| Operating cash flow | -$15.67M | -$11.87M |
| Investing cash flow | - | $0 |
| Financing cash flow | $27.08M | $11.74M |
| Stock-based compensation | $754.0K | $886.0K |
| Depreciation and amortization | $163.0K | $226.0K |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.95M | $1.15M | $1.01M | $1.19M | $2.13M | $620.0K | $836.0K | $881.0K | $694.0K | $1.98M |
| Cost of revenue | $2.34M | $875.0K | $598.0K | $1.32M | $2.26M | $978.0K | $700.0K | $1.55M | $1.08M | $1.17M |
| Gross profit | $616.0K | $275.0K | $411.0K | -$130.0K | -$127.0K | -$358.0K | $136.0K | -$673.0K | -$382.0K | $807.0K |
| Research and development | $1.37M | $1.90M | $547.0K | $951.0K | $743.0K | $808.0K | $789.0K | $961.0K | $940.0K | $690.0K |
| Selling, general and admin | $3.87M | $2.89M | $2.87M | $2.41M | $2.65M | $2.08M | $2.92M | $2.81M | $2.50M | $1.99M |
| Operating income | -$4.63M | -$4.51M | -$3.00M | -$3.49M | -$3.52M | -$3.25M | -$3.57M | -$4.44M | -$3.82M | -$1.87M |
| Interest expense | - | - | - | - | $2.43M | $555.0K | - | - | $172.0K | $82.0K |
| Pre-tax income | -$5.65M | -$7.62M | -$4.29M | -$10.43M | -$6.72M | -$5.53M | -$8.85M | -$6.21M | -$4.06M | -$1.95M |
| Income tax | $7.0K | $0 | $4.0K | $0 | $0 | $31.0K | -$15.0K | $0 | - | - |
| Net income | -$5.66M | -$7.62M | -$4.29M | -$10.43M | -$6.72M | -$5.56M | -$8.84M | -$6.21M | -$4.06M | -$1.95M |
| EPS, basic | -$3.05 | -$0.10 | - | -$0.19 | -$42.39 | -$0.80 | - | -$0.87 | - | - |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $38.0K | $121.0K | $7.45M | $2.81M | $410.0K | - | $96.0K | - | $78.0K | - |
| Receivables | - | - | - | - | $1.30M | - | $513.0K | - | - | - |
| Inventory | $5.97M | $7.45M | $7.30M | $6.55M | $7.00M | - | $8.12M | - | - | - |
| Current assets | $7.59M | $9.51M | $20.73M | $11.59M | $9.64M | - | $9.79M | - | - | - |
| Goodwill | $615.0K | $615.0K | $615.0K | $615.0K | $615.0K | - | $615.0K | - | - | - |
| Total assets | $9.17M | $11.22M | $22.55M | $13.52M | $11.70M | - | $12.11M | - | - | - |
| Current liabilities | $7.45M | $12.66M | $18.70M | $5.37M | $45.64M | - | $35.33M | - | - | - |
| Total liabilities | $7.45M | $12.67M | $18.76M | $5.55M | $45.93M | - | $35.84M | - | - | - |
| Shareholders' equity | $1.72M | -$1.45M | $3.79M | $7.97M | -$54.49M | -$48.92M | -$44.00M | -$35.40M | -$29.64M | -$25.77M |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.35M | -$3.80M | -$4.38M | -$6.51M | -$2.54M | -$2.24M | -$3.15M | -$2.61M | - | - |
| Capital expenditures | $0 | $26.0K | - | - | $0 | $0 | - | - | - | - |
| Free cash flow | -$1.35M | -$3.83M | - | - | -$2.54M | -$2.24M | - | - | - | - |
| Investing cash flow | $0 | -$26.0K | - | $0 | $0 | $0 | $0 | - | - | - |
| Financing cash flow | $1.25M | -$7.52M | $13.02M | $8.95M | $2.28M | $2.83M | $3.23M | $2.53M | - | - |
| Stock-based compensation | $1.38M | $165.0K | $226.0K | $204.0K | $183.0K | $141.0K | $226.0K | $435.0K | - | - |
| Depreciation and amortization | $45.0K | $46.0K | $40.0K | $41.0K | $442.1K | $42.0K | $42.0K | - | - | - |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 38.6% | 85.5% | 20.7% | 34.7% | 207.1% | -68.7% | - | - | - | - |
| Gross margin | 20.9% | 23.9% | 40.7% | -11.0% | -6.0% | -57.7% | 16.3% | -76.4% | -55.0% | 40.8% |
| Operating margin | -156.7% | -392.3% | -297.6% | -293.8% | -165.2% | -523.5% | -427.3% | -504.4% | -551.0% | -94.5% |
| Net margin | -191.6% | -662.3% | -425.3% | -878.3% | -315.5% | -896.9% | -1057.2% | -704.4% | -584.6% | -98.7% |
| Free cash flow margin | -45.8% | -332.7% | - | - | -119.2% | -361.5% | - | - | - | - |
| Current ratio | 1.02 | 0.75 | 1.11 | 2.16 | 0.21 | - | 0.28 | - | - | - |
Source: XBRL data Picard Medical Inc. files with the SEC, latest filing dated Aug 19, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| PMI | $6.30M | +41.0% | -$27.99M | -444.3% | $20.8M |
| SYK | $26.30B | +7.9% | $3.62B | 13.8% | $124.00B |
| MMM | $25.25B | +1.7% | $3.54B | 14.0% | $97.47B |
| BSX | $21.07B | +8.9% | $3.50B | 16.6% | $63.81B |
| BDX | $23.25B | +17.4% | $941.00M | 4.0% | $58.63B |
| MDLN | $30.68B | - | $683.00M | 2.2% | $53.55B |
| RMD | $5.73B | +9.0% | $1.59B | 27.8% | $33.16B |
| DXCM | $5.10B | +13.0% | $991.00M | 19.4% | $30.24B |
| WST | $3.40B | +12.6% | $638.90M | 18.8% | $28.78B |